经皮冠状动脉介入治疗中药物洗脱支架与裸金属支架的比较:随机临床试验的系统综述与个体患者数据Meta分析
该研究对20项随机试验的26616例患者进行个体患者数据Meta分析,比较新一代药物洗脱支架(DES)与裸金属支架(BMS)在经皮冠状动脉介入治疗后的结局。主要终点为心源性死亡或心肌梗死的复合终点。DES组主要终点风险较BMS组降低(HR 0.84,95%CI 0.78-0.90,p<0.001),主要归因于心肌梗死风险降低(HR 0.79,95%CI 0.71-0.88,p<0.001)。作者结论认为BMS不应再被视为安全性金标准。
要点
- DES组主要终点(心源性死亡或心肌梗死)风险较BMS组降低(HR 0.84,95%CI 0.78-0.90,p<0.001)。
- DES组心肌梗死风险较BMS组降低(HR 0.79,95%CI 0.71-0.88,p<0.001)。
- DES组明确支架内血栓风险较BMS组降低(HR 0.63,95%CI 0.50-0.80,p<0.001)。
核心结论
- 新一代DES在植入后第一年的表现意味着BMS不应再被视为安全性金标准。
- DES技术的进一步发展应着眼于改善1年以后的临床结局。
研究设计与样本
- 研究类型为随机临床试验的个体患者数据Meta分析,采用一阶段随机效应模型合并数据,并在最大随访时间和1年界标点进行分析。
- 共纳入20项随机试验的26616例患者,平均随访3.2年(标准差1.8年)。
- 主要终点为心源性死亡或心肌梗死的复合终点;风险估计以风险比(HR)及95%CI报告。
- 研究注册于PROSPERO,注册号CRD42017060520。
主要发现
- DES组主要终点风险较BMS组降低(HR 0.84,95%CI 0.78-0.90,p<0.001)。
- DES组心肌梗死风险较BMS组降低(HR 0.79,95%CI 0.71-0.88,p<0.001)。
- DES组心源性死亡风险较BMS组有轻微但非显著的降低(HR 0.89,95%CI 0.78-1.01,p=0.075)。
- DES组全因死亡风险与BMS组无显著差异(HR 0.96,95%CI 0.88-1.05,p=0.358)。
- DES组明确支架内血栓风险较BMS组降低(HR 0.63,95%CI 0.50-0.80,p<0.001),靶血管血运重建风险较BMS组降低(HR 0.55,95%CI 0.50-0.60,p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New-generation drug-eluting stents (DES) have mostly been investigated in head-to-head non-inferiority trials against early-generation DES and have typically shown similar efficacy and superior safety. How the safety profile of new-generation DES compares with that of bare-metal stents (BMS) is less clear. METHODS: We did an individual patient data meta-analysis of randomised clinical trials to compare outcomes after implantation of new-generation DES or BMS among patients undergoing percutaneous coronary intervention. The primary outcome was the composite of cardiac death or myocardial infarction. Data were pooled in a one-stage random-effects meta-analysis and examined at maximum follow-up and a 1-year landmark. Risk estimates are reported as hazard ratios (HRs) with 95% CIs. This study is registered in PROSPERO, number CRD42017060520. FINDINGS: We obtained individual data for 26 616 patients in 20 randomised trials. Mean follow-up was 3·2 (SD 1·8) years. The risk of the primary outcome was reduced in DES recipients compared with BMS recipients (HR 0·84, 95% CI 0·78-0·90, p<0·001) owing to a reduced risk of myocardial infarction (0·79, 0·71-0·88, p<0·001) and a possible slight but non-significant cardiac mortality benefit (0·89, 0·78-1·01, p=0·075). All-cause death was unaffected (HR with DES 0·96, 95% CI 0·88-1·05, p=0·358), but risk was lowered for definite stent thrombosis (0·63, 0·50-0·80, p<0·001) and target-vessel revascularisation (0·55, 0·50-0·60, p<0·001). We saw a time-dependent treatment effect, with DES being associated with lower risk of the primary outcome than BMS up to 1 year after placement. While the effect was maintained in the longer term, there was no further divergence from BMS after 1 year. INTERPRETATION: The performance of new-generation DES in the first year after implantation means that BMS should no longer be considered the gold standard for safety. Further development of DES technology should target improvements in clinical outcomes beyond 1 year. FUNDING: Bern University Hospital.
引用
- Piccolo R, Bonaa KH, Efthimiou O, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2019. PMID: 31056295. doi:10.1016/S0140-6736(19)30474-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。